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Background: This randomised cross-over pilot study was undertaken in 10 cystic fibrosis children aged 10 to 63 months to describe lung
absorption of tobramycin delivered by the PariLC+/PariTurboboyN (Pari GmbH) and the disposable NL9M/AtomisorBoxPlus (Diffusion
Technique Française) nebulising systems.
Methods: Each child inhaled 300 mg tobramycin delivered with one or the other apparatus via a facemask in two separate and
standardised sessions. Urine was collected for 6 h. Tobramycin concentrations determined by immunoprecipitation were expressed in mg
per g of creatinine and compared by a Wilcoxon test for matched pairs. The influences of age, weight and Brasfield score on this
parameter were evaluated by correlation tests, and those of sex, previous nebulisation treatment, and crying or coughing were evaluated by
Student's t-test.
Results: The amount of tobramycin measured in urines was low and variable. Median values for urinary tobramycin concentration were
47.6 mg/g (14.9–79.6) with the PariLC+ and 42.6 mg/g (6.3–112.8) with the NL9M (p=0.6). PariLC+ delivered tobramycin in 22 min and
NL9M in 12 min (p=0.005). Crying or coughing dramatically reduced the amount of tobramycin collected.
Conclusion: This pilot study shows that evaluation of nebulisers based on tobramycin renal excretion is feasible in young children with
cystic fibrosis.
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Bronchial infection with Pseudomonas aeruginosa is
always serious in children with cystic fibrosis. According to
the Observatoire National de la Mucoviscidose, 45% of
patients with cystic fibrosis are P. aeruginosa carriers in
France, and almost 25% of patients aged 0–4 years have
been infected at least once [1]. In patients diagnosed by
neonatal screening, 43% of children aged less than 7 years ined by Elsevier B.V. All rights reserved.
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in the USA are affected by P. aeruginosa [3]. The risk factors
for early infection with P. aeruginosa in these patients are
female sex, homozygous ΔF508 genotype, and isolation of
Staphylococcus aureus [4]. In one study [5], neonatal
screening itself was more frequently associated with P.
aeruginosa infection than in those who were not screened
(80% vs 60%, p=0.02), with lower ages at onset of infection
(3.01 years vs 6.04 years, p=0.007), possibly because of
earlier attendance at treatment centres.
Antibiotic treatment must be aggressive in early infection
with P. aeruginosa in order to have any possibility of
eradication [3]. Several treatment regimens have been
proposed, but most of them include the use of nebulised
aminoglycosides, either in combination or alternating with
other antibiotics [2,6–8].
Nebulisation is not easy in young children. The effec-
tiveness depends on the pulmonary deposition achieved. In
practice, deposition depends on the patient (e.g. age,
respiratory function), on the drug nebulised and its
physicochemical properties, on the apparatus used (which
mainly determines the particle size), and on the inhalation
technique [9]; the younger the child, the poorer the lung
deposition. The few scintigraphic lung deposition studies
undertaken in infants with cystic fibrosis show that only 1.3
to 2% of the nebulised drug reaches the lungs, that is about
10-fold lower than in adults [10,11]. Deposition can be
further reduced by bronchial obstruction, inhalation without
a facemask in young children (or mouthpiece in older
children), crying and screaming.
Tobi® (Chiron Laboratories, Paris, France) is the only
aminoglycoside officially registered for use by nebulisation.
It is mainly used in cystic fibrosis for bronchial infection
with P. aeruginosa, both during early infection and for
chronic colonisation [12]. The usual long term dose is
300 mg morning and evening daily during alternate months.
The apparatus dedicated for delivering Tobi® is the PariLC+
jet nebuliser combined with various compressors as the
PulmoAide (DeVilbiss, USA) or the new PariTurboBoyN
(PariGmbH, Munchen, Germany), more potent than the
PulmoAide and proposed by PariGmbH. Although admin-
istration of Tobi® with this equipment is effective in children
with cystic fibrosis under 6 years of age [8,13], the main
disadvantage is the need for careful washing, disinfection
and sterilization of the nebuliser after each use. In a recent
study we have conducted in nebulisation in cystic fibrosis,
47% of families considered that treatment by nebulisation
was difficult to administer on a daily basis and 84%
considered that disposable apparatus would be very helpful
[14]. The NL9M nebuliser (Diffusion Technique Française,
Saint-Etienne, France) is a disposable jet nebuliser whose
performance in vitro is comparable to that of the PariLC+
[15].
The aim of this study was to describe and explore the
pulmonary deposition of 300 mg tobramycin by measuring
renal excretion of this antibiotic delivered by these twonebulisers equipped with a facemask in children under
6 years of age with cystic fibrosis.
2. Materials and methods
2.1. Study subjects
Inclusion criteria were: to have a cystic fibrosis (genetic
mutations and 2 positive sweat tests), to be aged less than
6 years, to be regularly followed up in the Marseilles Cystic
Fibrosis Treatment Centre, to have a clinically stable disease,
to have a written consent for participation in the study from
both parents. Exclusion criteria were inability to attend the
Cystic Fibrosis Treatment Centre of the Timone University
Pediatric Hospital twice in a month, patent bronchial
infection at the time of inclusion, clinical bronchospasm,
known hypersensitivity to aminoglycosides, and current
treatment with Tobi®. However, children who had received
prior treatment with Tobi® could be included if none had
been received in the preceding week.
2.2. Study design
This was a randomised cross-over pilot study, approved
by the Ethics Committee of Aix-Marseille II, performed to
describe and explore the pulmonary deposition by measuring
renal excretion of tobramycin delivered by two different
nebulising systems. Tobramycin delivery was done in
children at two different sessions separated by at least a
week and no longer than a month.
2.3. Methods
2.3.1. Drugs and nebulisers
The drug used was tobramycin (Tobi®, 300 mg/5 ml
solution for inhalation) because, like other aminoglycosides,
tobramycin is considered to be a pharmacological tracer of
pulmonary deposition [16,17]. In fact, tobramycin is only
absorbed by the lungs, without any metabolisation. All the
tobramycin found in the blood or urine thus directly reflects
pulmonary absorption. Our primary end point was the
urinary tobramycin concentration.
The PariLC+/PariTurboBoyN combination (CE 0123)
was compared with the NL9M/AtomisorBoxPlus combina-
tion (CE 0459), both with paediatric facemasks (Fig. 1). Both
are breath-enhanced jet nebulisers. The facemask for the
PariLC+ has to be held in place on the child's face during
nebulisation, whereas that of the NL9M is kept in place by an
elastic strap adjusted to the size of the child's head.
2.3.2. Experimental protocol
After obtaining clinical history, all children were given a
complete clinical examination, during which anthropometric
measurements, pulmonary auscultation, pulsed oxygen
saturation rate, and resting respiratory rate measured over 1
min were recorded. Brasfield radiological scoring [18] was
Fig. 1. PariLC+ nebuliser (top: Pari GmbH, Munchen, Germany) and NL9M
nebuliser (bottom: Diffusion Technique Française, Saint-Etienne, France)
with their respective facemasks.
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within the preceding 3 months.
The children were asked to pass urine before beginning
the session, and Tobi® inhalation was standardised as much
as possible. The child was seated on the lap of his mother/
father with his head upright. One 300 mg ampoule of
tobramycin was placed directly in the reservoir of the
randomly selected nebuliser (PariLC+ or NL9M). Nebulisa-
tion was begun only when the facemask was in position,
meanwhile monitoring oxygen saturation by pulsed oxy-
metry. Respiration was required to be as calm as possible.
The nebuliser was maintained in an upright position, and
nebulisation was continuously monitored by two or three of
the investigators and was timed. Respiratory rate, chest
auscultation, crying, screaming and coughing were noted at
0, 1, 2, 5, 10 and 15 min, as well as any other side-effect,
and oxygen saturation. As recommended by Chiron
Laboratories for the use of Tobi®, nebulisation was stopped
when the apparatus appeared to be no longer delivering the
drug, as suspected by the absence of visible aerosol
production and the noise's change. The apparatus was
stripped down for cleaning according to current require-
ments at the end of nebulisation. The remaining solution in
the reservoir was aspirated by a syringe and the residual
volume was noted.
Hydration was maintained by normal alimentation
combined with administration of 100 mL water in a bottle
or cup just after completing nebulisation. Urine was
collected for 6 h. The children urinated directly into a
receptacle or a pouch (e.g. Urinocol®) according to age.
Urine was transferred to a sterile flask maintained at +4 °C
after each micturition. All micturitions obtained in 6 h were
pooled and tobramycin concentration was then measured in
fresh urines.A second nebulisation session took place under the same
conditions between 1 week and 1 month after the first to test
the second nebuliser.
2.3.3. Measurement of urinary tobramycin concentrations
Tobramycin concentrations are currently measured in our
hospital using an immunoprecipitation method called
PETINIA (particle enhanced turbidimetric inhibition immu-
noassay) using a RXL robot (Dade Behring, USA). As only
the measurement of plasma levels of tobramycin has been
validated by Dade Behring, the calibration curve for urinary
measurements was calculated from the plasmatic curve. We
validated urinary measurement by comparing several times
the concentrations measured in 6 samples of known
tobramycin concentrations (0.3, 1, 5, 10, 30, and 60 μg/
mL). The samples preparation was performed by adding
tobramycin in fresh and tobramycin-free urine. The lower
limit of quantification was 0.3 μg/mL. The accuracy
(expressed as a coefficient of variation) was less than 15%
at each of the 6 tobramycin concentrations and correlation
coefficient was 0.95. Reproducibility, also expressed as a
coefficient of variation, was less than 5%. Measurements
were performed on urinary samples stored at 4 °C and
bioassayed within 6 h after collection which is a situation
daily observed for this analysis. Systematic measurement of
urinary pH was also performed on all samples because the
measurement method was valid only for pH between 5 and 8.
Urinary creatinine was also measured.
2.3.4. Statistical analysis
Because this study was a pilot study we have chosen
arbitrary to enroll 10 children. Data are presented as median
values with extremes. The amount of tobramycin collected
was measured in urine collected over 6 h (mg/L) and then
expressed as mg/g of urinary creatinine to limit intra-subject
variations related to age or amount of urine collected. This
ratio, reflecting in this study the lung absorption of
tobramycin, was compared between nebulisers by Wilcoxon
test for matched pairs. As no data were available on renal
excretion of tobramycin in a young population of cystic
fibrosis children, we had no definitive criteria to propose for
proving similarity between both nebulisers. We postulated
that more than a 15% difference in tobramycin/creatinine
ratio between the two nebulisers would indicate non
equivalence of the apparatuses. The influences of age,
weight and Brasfield score on the tobramycin/creatinine ratio
were evaluated by simple, non-parametric correlation tests.
The influences of sex, previous use of a nebuliser and crying
and/or coughing during the nebulisation session were
evaluated by Student's t-test. A p value of less than 0.05
was considered to be statistically significant.
3. Results
On the 16 eligible children of our Cystic Fibrosis
Treatment Centre, 2 refused to participate to the study and
Table 1
Clinical characteristics of the 10 children with cystic fibrosis
Age
(months)
Sex Weight (kg) Height (cm) Shwachman
Score
Brasfield
Score
Habituated to
nebulisation
10 F 9.3 (+1S.D.) 74 (+1S.D.) 95/100 2/25 Yes
16 M 13 (+2S.D.) 82 (+2S.D.) 95/100 0/25 Yes
17 M 10.1 (−1S.D.) 75 (−1S.D.) 95/100 0/25 No
23 M 11 (−1S.D.) 83.5 (−1S.D.) 90/100 4/25 Yes
33 M 10.8 (−2S.D.) 87 (−1S.D.) 90/100 1/25 No
39 F 12.5 (−1S.D.) 88 (−2S.D.) 95/100 1/25 Yes
46 M 12 (−2S.D.) 93 (−2S.D.) 80/100 6/25 No
49 M 13.2 (−1S.D.) 94 (−1S.D.) 90/100 1/25 No
57 F 15 (−1S.D.) 100 (−2S.D.) 80/100 5/25 Yes
63 F 16.5 (−1S.D.) 111 normal 80/100 8/25 Yes
M=male; F=female; S.D.=Standard deviation.
Fig. 2. Individual ratio of tobramycin/creatinine obtained in 10 children with
cystic fibrosis after inhaling 300 mg tobramycin with a PariLC+ and a
NL9M nebuliser.
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median age of the 10 remainder cystic fibrosis children (6
boys) was 35.3 months, range 10 to 63 months (Table 1).
Median Shwachman score was 89/100 (80–95). All the
children had experienced several bronchial infections since
diagnosis, but the last sputum sample before initiating the
study was sterile in 8 of the 10 children. Four children were
currently being treated with nebulised tobramycin at home
and 6 of 10 had already experienced nebulisation. The
median Brasfield radiological score was 2.8/25 (0–8).
Auscultation was normal for nine children, and the tenth
had crackles during both nebulisation sessions. Measure-
ment of respiratory rate revealed normal values for age,
ranging from 40 per min in an infant of 23 months to 15 per
min for a child of 57 months. Median pulsed oxymetry value
before the nebulisation sessions began was 97% (94–100%).
All the children completed the protocol. Two children
had three nebulisation sessions instead of two, in one case
because complete urine collections were impossible to
collect, and in the other because the nebuliser was knocked
over during the nebulisation process. No severe side-effect
occurred. No hypoxaemia or wheezing episodes occurred
during nebulisation. Monitoring respiratory rates did not
reveal any variations during nebulisation, nor was there any
difference between the two nebulisers. Median respiratory
rate was 27.5 per min with the PariLC+ and 28.8 per min
with the NL9M. Coughing or crying occurred during eight
nebulisation sessions, four with each apparatus, and
involved five children. Three had a slight cough (1 with
the PariLC+, 1 with the NL9M and 1 with both), and two
(the two youngest patients) cried throughout, in one case
necessitating premature withdrawal from nebulisation with
the PariLC+.
Median duration of nebulisation was 22 min (13–28 min)
for the PariLC+ and 12 min (10–19 min) for the NL9M
(p=0.005). When the shortest period of 13 min in the case of
the elective cessation of the session with the PariLC+ for
continuous crying was not included, a 50% decrease was
noted in duration with the NL9M.
There was no significant difference between the PariLC+
and the NL9M in terms of median residual volume oftobramycin remaining in the nebulisation reservoir indicat-
ing that nearly the same volume of aerosol was available for
inhalation with both nebulisers (0.83 mL, range 0.22 to 1.4,
and 0.74 mL, range 0.42 to 1.7, respectively; p=0.87). Any
relationship between residual volume and duration of
nebulisation was observed in this study.
Median diuresis over the 6 h was 128.5 mL (30–
325 mL), and was similar for both nebulisers (124.9 mL for
the PariLC+ and 132.2 mL for the NL9M). The amount of
tobramycin found in the urine was low, and varied
considerably between children and even from one nebulisa-
tion session to another for the same child, from 0.13 to
7.70 mg/L (median of 2.6 mg for the PariLC+ and 2.2 mg
for the NL9M; p=0.2). The same trend was found for the
tobramycin/creatinine ratio (Fig. 2). As shown in Fig. 2, the
inter-subjects variability was more important than the intra-
subjects (or inter-nebulisers for a same child) variability.
The ratio between subjects was highly variable from 6.3 mg/
g to 112.8 mg/g, whereas in a same subject this ratio ranged
from 1.2 to 41.4mg/g. A 15% difference on this ratio between
nebulisers was noted in 50% of the subjects. Median values
for urinary tobramycin/creatinine concentration (Fig. 3) were
Fig. 3. Median values of the ratio tobramycin/creatinine obtained in
10 children with cystic fibrosis after inhaling 300 mg tobramycin with a
PariLC+ and a NL9M nebuliser.
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112.8) with the NL9M (p=0.6).
No influence of age, weight, Brasfield score or
familiarity with nebulisation was revealed by the parameter
measured with either apparatus. On the other hand, crying
and/or coughing significantly reduced the amount of
urinary tobramycin collected over 6 h (1 vs 3.8 mg;
p=0.03), but did not affect the ratio tobramycin/creatinine
for both nebulisers (41.3 vs 51.8 mg/g for the PariLC+,
p=0.43; and 26.0 vs 63.7 mg/g for the NL9M, p=0.11).
When the nebulisation sessions with crying and/or cough-
ing were omitted from the results, the median age of the
children was 47.5 months in both groups, and the median
urinary tobramycin concentrations were not significantly
different between nebulisers (49.3 mg/g (32.5–69.2) for the
PariLC+ and 59.0 mg/g (12.3–112.8) for the NL9M;
p=0.52).
4. Discussion
This randomised cross-over pilot study demonstrates that
measuring renal excretion of tobramycin for comparing the
pulmonary deposition obtained with two different nebulisers
in children with cystic fibrosis aged less than 6 years is
possible, but that the ratio tobramycin/creatinine in this age
range is low and highly variable.
There are many methods of studying pulmonary deposi-
tion of inhaled drugs, mainly based on in vitro, scintigraphic,
pharmacokinetic and pharmacodynamic techniques [19].
Pulmonary scintigraphy is one of the most valuable methods
but such studies are rare in children, particularly in the
youngest ones, because of practical difficulties in view of
problems such as irradiation. Pharmacokinetics studies
measure the drug which is absorbed by the lung surface.
They are usually based on the determination of the drug
concentration in the plasma or urine. Such studies are
difficult to perform. The main stumbling block is to measure
all the drug absorbed both by the lungs and by the upper
respiratory and gastro-intestinal tracts [19]. This can partlybe avoided through maximum standardisation of the
inhalation technique, by monitoring variations in urinary
excretion and by using only drugs that are exclusively
absorbed by the lungs. Tobramycin was chosen to compare
the ability of the NL9M and Pari LC+ nebulisers to deliver
drugs because it is one of the few drugs which is
administered via the airways and it is only absorbed by the
lungs without any metabolisation. Urinary excretion is thus
total [17]. We preferred to express the amount of tobramycin
collected per g of creatinine to limit intra-subject variations,
without limiting inter-subject variability.
After 300 mg tobramycin inhalation, peak serum
concentration occurs in 1 h and then decreases progressively
over 2 h reaching negligible levels after 4 h, even in young
children with cystic fibrosis [13,20]. However, a long and
variable terminal half life has been described after 600 mg
tobramycin nebulisation in adults (mean 9.47±3.28 h) [21].
In another study [17], 2 subjects out of 6 have detectable
urinary tobramycin concentrations at or just above the limit
of detection for each of the four 12-h collection intervals.
These subjects were female and had the same pharmacoki-
netic profile with the 3 tobramycin doses tested (80, 160, and
320 mg) [17]. In our study, urinary concentration of
tobramycin over 6 h probably does not correspond to the
total amount of tobramycin absorbed by the lungs, but it was
likely sufficient to make a comparison in a same child
between the two nebulisation apparatuses, particularly when,
as in our study, urine collections over 6 h were complete for
all children. Moreover, it was really difficult to keep quiet
young children equipped with a urine pouch for a longer time
(total duration of the study including clinical examination,
nebulisation session and urine collection was about 8 h).
Because of the extreme difficulty to obtain several urine
samples at fixed periods in young children without invasive
methods, particularly in a same child on 2 different study
days, tobramycin elimination curve has not been character-
ized, and our study cannot be considered as a true
pharmacokinetic study.
Some bias must be considered in our study. Firstly, it is
difficult to standardise nebulisation techniques in young
children (2 of the 10 children had to return for a third session
for technical reasons, 2 others cried continuously), and it is
difficult to standardise urine collection, the volume of which
is variable according to the session and age. The latter
problem can be overcome by expressing urinary tobramycin
concentration as mg/g creatinine. In addition, the small
study group reduces the power of the study, particularly as
there were considerable variations in measurements from
child to child. The design of the study fails to prove
equivalence of both nebulisers as we have defined it, but a
similar profile of tobramycin renal excretion for both
nebulisers, PariLC+ and NL9M, is found in children under
6 years of age with cystic fibrosis. A nebulisation time half
as long and a disposable equipment are great advantages for
the NL9M/AtomisorBoxPlus combination with facemask.
Indeed, these two elements facilitate the use of this
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treatment compliance. On the other hand, we have to limit
our enthusiastic conclusions firstly because toxicity, which
has to be evaluated on plasma levels of tobramycin, has not
been determined in this study, and secondly because a
population of 10 patients is not enough to prove a real
equivalence between the studied nebulisers.
We are unable to precisely quantify the pulmonary
deposition, but it was not the aim of this pilot study.
However, lung absorption of tobramycin appears to be very
low, and highly variable between subjects. Conversely,
inter-nebulisers variability is less important. In contrast to
results published with other nebulised drugs, sex, age and
weight were not found to have any influence on lung
absorption [22]. We were also unable to demonstrate any
relationship between parameters of pulmonary absorption of
tobramycin and Brasfield score, but our patients fortunately
had low levels of respiratory involvement. It was more
surprising that there was no correlation between the
tobramycin/creatinine ratio and previous use of nebulised
treatment at home, which might have supposed a positive
effect of prior learning. On the other hand, a three- or four-
fold decrease in urinary tobramycin concentration was noted
with both nebulisers when there was crying and/or
coughing. This might be explained by changes in the site
of deposition of the drug in the body, with increased naso-
pharyngeal and gastro-intestinal deposition rather than
pulmonary deposition [23]. Therefore, this result was not
confirmed when tobramycin was expressed in mg per g of
creatinine, maybe because only 10 children were explored.
Therefore in view of these findings, it would seem
preferable to perform nebulisation in the youngest children
with rapid delivery equipment in order to achieve optimal
pulmonary deposition, possibly when they are calm such as
during sleep.
In conclusion, this pilot study describes and explores the
pulmonary deposition by measuring renal excretion of
tobramycin delivered by two different nebulisers equipped
with a facemask in cystic fibrosis children under 6 years.
The main factor which influences the amount of drug
delivered to the lungs in this study is the occurrence of
crying and/or coughing during the nebulisation session. This
suggests that it would be preferable to use rapid nebulisers in
periods when young children are calm. Other studies,
conducted with an appropriate number of young cystic
fibrosis patients and based on renal excretion of tobramycin,
could be particularly interesting by comparing the fast and
disposable NL9M nebuliser to the new nebulisers using a
vibrating membrane which deliver 150 mg of tobramycin in
vitro in 3 min [24], although they may be less easy to
disinfect.
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